Styliani Giannakaki

Suggest Changes
We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE To assess the overall survival (OS) of metastatic hormone-refractory prostate cancer (mHRPC) patients when treated with zoledronic acid (ZOL) in combination with docetaxel-based chemotherapy(More)
BACKGROUND/AIMS Although research on new effective treatments against pancreatic cancer is intense, limited therapeutic schemes are currently approved. The aim of the present study was to record the(More)
  • 1